Literature DB >> 31661640

HMGB2 is a negative regulator of telomerase activity in human embryonic stem and progenitor cells.

Martin Kučírek1, Alireza J Bagherpoor1, Josef Jaroš2,3, Aleš Hampl2,3, Michal Štros1.   

Abstract

High-mobility group box (HMGB)1 and HMGB2 proteins are the subject of intensive research because of their involvement in DNA replication, repair, transcription, differentiation, proliferation, cell signaling, inflammation, and tumor migration. Using inducible, stably transfected human embryonic stem cells (hESCs) capable of the short hairpin RNA-mediated knockdown (KD) of HMGB1 and HMGB2, we provide evidence that deregulation of HMGB1 or HMGB2 expression in hESCs and their differentiated derivatives (neuroectodermal cells) results in distinct modulation of telomere homeostasis. Whereas HMGB1 enhances telomerase activity, HMGB2 acts as a negative regulator of telomerase activity in the cell. Stimulation of telomerase activity in the HMGB2-deficient cells may be related to activation of the PI3K/protein kinase B/ glycogen synthase kinase-3β/β-catenin signaling pathways by HMGB1, augmented TERT/telomerase RNA subunit transcription, and possibly also because of changes in telomeric repeat-containing RNA (TERRA) and TERRA-polyA+ transcription. The impact of HMGB1/2 KD on telomerase transcriptional regulation observed in neuroectodermal cells is partially masked in hESCs by their pluripotent state. Our findings on differential roles of HMGB1 and HMGB2 proteins in regulation of telomerase activity may suggest another possible outcome of HMGB1 targeting in cells, which is currently a promising approach aiming at increasing the anticancer activity of cytotoxic agents.-Kučírek, M., Bagherpoor, A. J., Jaroš, J., Hampl, A., Štros, M. HMGB2 is a negative regulator of telomerase activity in human embryonic stem and progenitor cells.

Entities:  

Keywords:  HMGB1; hESCs; neuroectodermal cells; telomeres

Mesh:

Substances:

Year:  2019        PMID: 31661640     DOI: 10.1096/fj.201901465RRR

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  6 in total

Review 1.  The role of high mobility group protein B3 (HMGB3) in tumor proliferation and drug resistance.

Authors:  Bin Wen; Ying-Ting Wei; Kui Zhao
Journal:  Mol Cell Biochem       Date:  2021-01-11       Impact factor: 3.396

2.  Newly identified breast luminal progenitor and gestational stem cell populations likely give rise to HER2-overexpressing and basal-like breast cancers.

Authors:  James R W McMullen; Ubaldo Soto
Journal:  Discov Oncol       Date:  2022-05-28

3.  Single-cell RNA Sequencing Uncovered the Involvement of an Endothelial Subset in Neutrophil Recruitment in Chemically Induced Rat Pulmonary Inflammation.

Authors:  Hong Huang; Ying Yang; Tingting Song; Yongfeng Yang; Yihan Zhu; Zhiqiang Liu; Li Li; Xuedong Wang
Journal:  Int J Med Sci       Date:  2022-03-28       Impact factor: 3.642

4.  Nonhistone Proteins HMGB1 and HMGB2 Differentially Modulate the Response of Human Embryonic Stem Cells and the Progenitor Cells to the Anticancer Drug Etoposide.

Authors:  Alireza Jian Bagherpoor; Martin Kučírek; Radek Fedr; Soodabeh Abbasi Sani; Michal Štros
Journal:  Biomolecules       Date:  2020-10-15

5.  HMGA2 Promotes Brain Injury in Rats with Cerebral Infarction by Activating TLR4/NF-κB Signaling Pathway.

Authors:  Shaoyue Huang; Zhen Hong; Leguo Zhang; Jian Guo; Yanhua Li; Kuo Li
Journal:  Mediators Inflamm       Date:  2022-08-04       Impact factor: 4.529

6.  The general law of plasma proteome alterations occurring in the lifetime of Chinese individuals reveals the importance of immunity.

Authors:  Xiaolin Ni; Juan Jiao; Ze Yang; Zhaoping Wang; Nan Nan; Danni Gao; Liang Sun; Xiaoquan Zhu; Qi Zhou; Nan Zhang; Zhu Wu; Shenqi Zhang; Huiping Yuan
Journal:  Aging (Albany NY)       Date:  2022-09-07       Impact factor: 5.955

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.